Haemonetics FY2026 EPS Forecast Boosted by Zacks Research

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research raised their FY2026 earnings per share (EPS) estimates for Haemonetics in a research note issued on Monday, December 9th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $5.18 per share for the year, up from their prior forecast of $5.17. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.99 EPS.

HAE has been the topic of several other research reports. JPMorgan Chase & Co. started coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Haemonetics in a research note on Tuesday, August 13th. Bank of America began coverage on shares of Haemonetics in a report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a report on Tuesday, December 3rd. Finally, CL King began coverage on shares of Haemonetics in a research report on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $108.78.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $83.84 on Wednesday. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of 34.80, a P/E/G ratio of 1.26 and a beta of 0.38. Haemonetics has a 1-year low of $70.25 and a 1-year high of $97.97. The firm’s 50-day moving average price is $80.73 and its two-hundred day moving average price is $81.65. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39.

Institutional Investors Weigh In On Haemonetics

Several institutional investors have recently bought and sold shares of the company. Quarry LP bought a new position in shares of Haemonetics in the 2nd quarter valued at about $39,000. Daiwa Securities Group Inc. acquired a new position in Haemonetics during the second quarter valued at approximately $82,000. Canada Pension Plan Investment Board bought a new position in Haemonetics in the second quarter valued at approximately $83,000. Nisa Investment Advisors LLC increased its position in shares of Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Haemonetics in the 2nd quarter valued at approximately $140,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.